nab-paclitaxel + carboplatin + gemcitabine

nab-paclitaxel + carboplatin + gemcitabine is a combination chemotherapy regimen evaluated as a neoadjuvant treatment for patients with locally advanced, muscle-invasive bladder cancer. The regimen includes ABI-007 (nab-paclitaxel), which is an albumin-bound nanoparticle formulation of paclitaxel designed to enhance drug delivery to tumors via albumin receptor-mediated transport while avoiding the toxicities associated with conventional paclitaxel solvents like Cremophor EL. This is combined with carboplatin, a platinum-based antineoplastic agent that induces DNA cross-linking, and gemcitabine, a nucleoside analog that inhibits DNA synthesis. The University of Michigan Rogel Cancer Center conducted a Phase 2 trial to assess the safety and efficacy of this triplet combination prior to radical cystectomy in patients whose cancer has invaded the bladder muscle wall.

Brand names

Abraxane

Other names

ABI-007 + carboplatin + gemcitabinenanoparticle albumin-bound paclitaxel + carboplatin + gemcitabine